SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ENTX reported Three months ended September 30, 2026 results. The price and volatility reaction is pending.
ENTXearnings

Earnings reactions, page 4

Entera Bio Ltd. (ENTX) FY2026 earnings

November 7, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $4.9 million for the three months ended September 30, 2026.
  • General and administrative expenses were $2.3 million for the three months ended September 30, 2026.
  • Net loss was $15.6 million, or $0.11 per ordinary share (basic and diluted), for the three months ended September 30, 2026.
  • Cash and cash equivalents were $265.9 million as of September 30, 2026.
  • Restricted cash was $6.5 million as of September 30, 2026.

Guidance

  • Entera is preparing to activate the first clinical site for the Phase 3 study in late 2026.
  • Topline results for the Phase 3 study are anticipated in the second half of 2028.
  • Entera plans to initiate a Phase 1 single ascending dose (SAD) study for EB612 in 2027.

Notes

Net loss for the period was impacted by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →